Dublin, July 24, 2017 -- The "Global Nerve Repair Biomaterials Market - Trends and Forecast to 2024" report has been added to Research and Markets' offering.
Global Nerve Repair Biomaterials Market is Expected to Reach USD 775.6 Million by 2024, at a CAGR of 11.3% During the Forecast Period of 2017 to 2024
The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
The global nerve repair biomaterials market is witnessing a rapid growth due to increasing geriatric population, increasing incidence of nerve injuries and neurological disorders, favourable reimbursement policies, and increased government funding. The demand for nerve repair biomaterials is increasing in the hospitals followed by ambulatory trauma centres due to increasing aging population and rising number of nerve injuries and nerve surgeries.
Key Topics Covered:
1 Introduction
1.1. Overview of the Nerve Repair Biomaterials Market
1.2. Market Segmentation & Coverage
1.2.1. Currency and Pricing
1.2.2. Limitation
1.2.3. Stakeholders
2 Research Methodology
2.1. Key Takeaways
2.2. Arriving at the Global Nerve Repair Biomaterials Market Size
2.2.1. Market Crackdown Approach
2.2.2. Company Revenue and Market Share Analysis
2.2.3. Data Triangulation
2.2.4. Key Data Points from Primary Sources
2.2.5. Key Data Points from Secondary Sources
2.2.6. Porter's Five Forces Matrix
2.4. Global Nerve Repair Biomaterials Market: Research Snapshot
2.5. Assumptions
3 Market Landscape Summary
4 Premium Insights
4.1. Overview
4.2. Global Nerve Repair Biomaterials Market: Key Primary Insights
4.3. Market Overview
4.3.1. Drivers
4.3.1.1. Increasing Incidences of Peripheral Nerve Injuries
4.3.1.2. Technological Development in Nerve Repair
4.3.1.3. Favorable Reimbursement Policies
4.3.1.4. Expanded Target Applications
4.3.2. Restraints
4.3.2.1. Lack of Patient Awareness
4.3.2.2. Lack of Professionals, Including Trained Surgeons
4.3.3. Opportunities
4.3.3.1. Novel Therapies Such as Stem Cell Therapy
4.3.3.2. Rising Acceptance of Emerging Markets
4.3.4. Threats
4.3.4.1. Donor Site Morbidity
4.3.4.2. Inadequate Nerve Regeneration by Conduits
4.4. Key Market Trends and Upcoming Technologies
5 Executive Summary
6 Nerve Repair Biomaterials Market, by Product Type
6.1. Overview
6.2. Nerve Repair
6.2.1. Nerve Conduits
6.2.2. Nerve Grafts
6.2.2.1. Allografts
6.2.2.2. Acellularized Allografts
6.3. Nerve Protection
6.3.1. Nerve Protector
6.3.2. Nerve Wrap
7 Nerve Repair Biomaterials Market, by Injury Type
7.1. Overview
7.2. Epineural Nerve Repair
7.3. Perineural Nerve Repair
7.4. Group Fascicular Nerve Repair
8 Nerve Repair Biomaterials Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Ambulatory Trauma Centers
8.4. Clinics
9 Nerve Repair Biomaterials Market, by Geography
10 Nerve Repair Biomaterials Market: Competitive Landscape
11 Nerve Repair Biomaterials Market, Company Profiles
- Axogen, Inc.
- Checkpoint Surgical, Inc.
- Collagen Matrix, Inc.
- Integra Lifesciences Corporation
- Polyganics B.V.
- Stryker Corporation
- Synovis Micro Companies Alliance, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/hzf5jb/global_nerve
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics, Biomaterials


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



